Company intelligence / Profile preview

Point Therapeutics

Wellesley Hills, Massachusetts, United Statestenpointtherapeutics.com ↗

Ownership: Private
Development stage: Other

Overview

Point Therapeutics developed talabostat and studied it in several Phase 2 and Phase 3 trials for various cancers. In May 2007, interim results led to the halting of two Phase 3 studies in advanced non-small cell lung cancer. The FDA subsequently put the clinical program on hold. Due to cash limitations, internal research and clinical operations ceased prior to acquisition.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Point Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Point Therapeutics.

Explore the full profile